Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Equity Ratio: 2019-2025

Historic Equity Ratio for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to 0.86.

  • Kymera Therapeutics' Equity Ratio fell 0.49% to 0.86 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.86, marking a year-over-year decrease of 0.49%. This contributed to the annual value of 0.85 for FY2024, which is 24.55% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Equity Ratio stood at 0.86, which was down 0.03% from 0.86 recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Equity Ratio high stood at 0.86 for Q3 2024, and its period low was 0.59 during Q1 2021.
  • For the 3-year period, Kymera Therapeutics' Equity Ratio averaged around 0.80, with its median value being 0.83 (2024).
  • In the last 5 years, Kymera Therapeutics' Equity Ratio spiked by 30.18% in 2021 and then dropped by 15.59% in 2023.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Equity Ratio stood at 0.76 in 2021, then grew by 7.13% to 0.81 in 2022, then fell by 15.59% to 0.69 in 2023, then climbed by 24.55% to 0.85 in 2024, then fell by 0.49% to 0.86 in 2025.
  • Its last three reported values are 0.86 in Q3 2025, 0.86 for Q2 2025, and 0.86 during Q1 2025.